Dr.MetabolicMD said:

I have been dealing with this for almost 2 years now, and what I have found is that individual respo

I respect Dr.MetabolicMD perspective but I think this oversimplifies things a bit. Re: GLP-1 therapy in patients over — the effect size varies considerably by population.

I am not saying Dr.MetabolicMD wrong entirely — just that the picture is more nuanced than a blanket statement. The SURMOUNT data specifically shows baseline BMI-dependent responses.

Relevant to GLP-1 therapy in patients over — here is my latest bloodwork comparison:

Key improvements: A1C 7.2% → 5.3%, triglycerides 243 → 113 mg/dL, hsCRP 6.0 → 1.3 mg/L. All on tirzepatide for 11 months.

The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.

Thank you pat_auckland! This is incredibly helpful. Bookmarking for later. 🙏

Slightly tangential to GLP-1 therapy in patients but SurmountFan_IN reminded me — has the insurance landscape changed recently?

I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.

Moderator note: Reminder: nothing posted here constitutes medical advice. Consult your healthcare provider.

Tagging this for the weekly digest. 👍